SNA014 for stomach and pancreatic cancer
Part of Cancer clinical trials.
This trial is testing a new treatment called SNA014 for people with stomach, gastroesophageal junction, or pancreatic cancer. It looks for a specific protein called Claudin18.2 on your tumor cells and aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer.
- You have had a recent scan (like a CT or MRI) within the past month, if available.
- You have a tumor test result for Claudin18.2 from the past year, if available.
- You are not pregnant or breastfeeding, and you agree to use birth control if needed.
- You do not have any other active cancer or serious uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new drug called SNA014 for pancreatic cancer. The drug targets a specific protein marker (Claudin-18.2) on cancer cells, and researchers want to see if it's safe and effective for patients whose tumors have this marker.
This study tests a new type of PET scan (a special imaging test) that can detect a protein called claudin 18.2 in pancreatic cancer and stomach cancer. The scan may help doctors better understand your cancer and plan treatment.
This trial tests the safety and side effects of SHR-A1904, and whether it can help people with advanced stomach or pancreatic cancer. To join, your tumor must have high “Claudin 18.2” protein, and you must meet several health and timing requirements.
This early-stage trial tests a new radioactive drug (177Lu-DOTA-SNA040) designed to target a protein called Claudin18.2 found on certain cancer cells. The drug delivers radiation directly to tumors in patients with advanced gastric, pancreatic, or bile duct cancers that have stopped responding to standard treatments.
This trial is testing an investigational drug called AZD5863 for people whose stomach, esophagus, or pancreatic cancer has spread and hasn't responded to at least one previous treatment. The study aims to see if targeting a protein called Claudin 18.2 on tumor cells can help shrink or slow the cancer.
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Hear when a new Adenocarcinoma of the Stomach trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.